Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia Syndrome
Opsoclonus myoclonus ataxia syndrome (OMS) is a rare neurologic syndrome. In a high proportion of children, it is associated with neuroblastoma. The etiology of this condition is thought to be immune mediated. In children, immunotherapy with conventional treatments such as corticosteroids, intraveno...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2012/164082 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850166739426344960 |
|---|---|
| author | Samin Alavi Ali Kord Valeshabad Borhan Moradveisi Ali Aminasnafi Mohammad Taghi Arzanian |
| author_facet | Samin Alavi Ali Kord Valeshabad Borhan Moradveisi Ali Aminasnafi Mohammad Taghi Arzanian |
| author_sort | Samin Alavi |
| collection | DOAJ |
| description | Opsoclonus myoclonus ataxia syndrome (OMS) is a rare neurologic syndrome. In a high proportion of children, it is associated with neuroblastoma. The etiology of this condition is thought to be immune mediated. In children, immunotherapy with conventional treatments such as corticosteroids, intravenous immunoglobulin, adrenocorticotropic hormone, and even antiepileptic drugs has been tried. Recently rituximab has been used safely for refractory OMS in children with neuroblastoma. Our patient was a 3.5-year-old girl referred for ataxia and dancing eye movements starting since 1.5 years ago. She was diagnosed with neuroblastoma on imaging studies on admission. The OMS was refractory to surgical resection, chemotherapy, corticosteroids, and intravenous immunoglobulin. Patient received rituximab simultaneously with chemotherapy. The total severity score decreased by 61.1% after rituximab. Patient's ataxia markedly improved that she was able to walk independently after 6 months. Our case confirmed the clinical efficacy and safety of rituximab in a refractory case of OMS. |
| format | Article |
| id | doaj-art-de8be25455dc437f9201b840410958d6 |
| institution | OA Journals |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-de8be25455dc437f9201b840410958d62025-08-20T02:21:21ZengWileyCase Reports in Oncological Medicine2090-67062090-67142012-01-01201210.1155/2012/164082164082Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia SyndromeSamin Alavi0Ali Kord Valeshabad1Borhan Moradveisi2Ali Aminasnafi3Mohammad Taghi Arzanian4Pediatric Hematology and Oncology Department, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran 15468-15514, IranDivision of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, MD 21218, USAPediatric Hematology and Oncology Department, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran 15468-15514, IranPediatric Hematology and Oncology Department, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran 15468-15514, IranPediatric Hematology and Oncology Department, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran 15468-15514, IranOpsoclonus myoclonus ataxia syndrome (OMS) is a rare neurologic syndrome. In a high proportion of children, it is associated with neuroblastoma. The etiology of this condition is thought to be immune mediated. In children, immunotherapy with conventional treatments such as corticosteroids, intravenous immunoglobulin, adrenocorticotropic hormone, and even antiepileptic drugs has been tried. Recently rituximab has been used safely for refractory OMS in children with neuroblastoma. Our patient was a 3.5-year-old girl referred for ataxia and dancing eye movements starting since 1.5 years ago. She was diagnosed with neuroblastoma on imaging studies on admission. The OMS was refractory to surgical resection, chemotherapy, corticosteroids, and intravenous immunoglobulin. Patient received rituximab simultaneously with chemotherapy. The total severity score decreased by 61.1% after rituximab. Patient's ataxia markedly improved that she was able to walk independently after 6 months. Our case confirmed the clinical efficacy and safety of rituximab in a refractory case of OMS.http://dx.doi.org/10.1155/2012/164082 |
| spellingShingle | Samin Alavi Ali Kord Valeshabad Borhan Moradveisi Ali Aminasnafi Mohammad Taghi Arzanian Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia Syndrome Case Reports in Oncological Medicine |
| title | Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia Syndrome |
| title_full | Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia Syndrome |
| title_fullStr | Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia Syndrome |
| title_full_unstemmed | Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia Syndrome |
| title_short | Clinical Responses to Rituximab in a Case of Neuroblastoma with Refractory Opsoclonus Myoclonus Ataxia Syndrome |
| title_sort | clinical responses to rituximab in a case of neuroblastoma with refractory opsoclonus myoclonus ataxia syndrome |
| url | http://dx.doi.org/10.1155/2012/164082 |
| work_keys_str_mv | AT saminalavi clinicalresponsestorituximabinacaseofneuroblastomawithrefractoryopsoclonusmyoclonusataxiasyndrome AT alikordvaleshabad clinicalresponsestorituximabinacaseofneuroblastomawithrefractoryopsoclonusmyoclonusataxiasyndrome AT borhanmoradveisi clinicalresponsestorituximabinacaseofneuroblastomawithrefractoryopsoclonusmyoclonusataxiasyndrome AT aliaminasnafi clinicalresponsestorituximabinacaseofneuroblastomawithrefractoryopsoclonusmyoclonusataxiasyndrome AT mohammadtaghiarzanian clinicalresponsestorituximabinacaseofneuroblastomawithrefractoryopsoclonusmyoclonusataxiasyndrome |